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Abstract
Background: Metformin is widely used to treat gestational diabetes (GDM), but many women remain hyperglycaemic
and require additional therapy. We aimed to determine recruitment rate and participant throughput in a randomised
trial of glibenclamide compared with standard therapy insulin (added to maximum tolerated metformin) for treatment
of GDM.
Methods: We conducted an open label feasibility study in 5 UK antenatal clinics among pregnant women 16 to 36 weeks’
gestation with metformin-treated GDM. Women failing to achieve adequate glycaemic control on metformin monotherapy
were randomised to additional glibenclamide or insulin. The primary outcome was recruitment rate. We explored feasibility
with uptake, retention, adherence, safety, glycaemic control, participant satisfaction and clinical outcomes.
Results: Records of 197 women were screened and 23 women randomised to metformin and glibenclamide
(n = 13) or metformin and insulin (n = 10). Mean (SD) recruitment rate was 0.39 (0.62) women/centre/month.
9/13 (69.2%, 95%CI 38.6–90.9%) women adhered to glibenclamide and all provided outcome data (100% retention).
There were no episodes of severe hypoglycaemia, but metformin and insulin gave superior glycaemic control to
metformin and glibenclamide, with fewer blood glucose readings <3.5 mmol/l (median [IQR] difference/woman/week
of treatment 0.58 [0.03–1.87]).
Conclusions: A large randomised controlled trial comparing glibenclamide or insulin in combination with metformin
for women with GDM would be feasible but is unlikely to be worthwhile, given the poorer glycaemic control with
glibenclamide and metformin in this pilot study. The combination of metformin and glibenclamide should be reserved
for women with GDM with true needle phobia or inability to use insulin therapy.
Trial registration: www.clinicaltrials.gov registration number:NCT02080377 February 11th 2014.
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Background
Gestational diabetes mellitus (GDM), defined as carbo-
hydrate intolerance of variable severity with onset or
first recognition during pregnancy [1], is associated with
increased risks of perinatal mortality and morbidity.
Glucose lowering treatment in women with GDM
improves outcomes including reducing birth weight, the
proportion of large for gestational age infants, caesarean
section and perinatal morbidity [2, 3]. Lowering diagnos-
tic thresholds [1, 4, 5], and an increasing prevalence of
risk factors such as obesity have led to many more
women being diagnosed with GDM and requiring
glucose lowering treatment.
Insulin has traditionally been the first drug of choice
for treatment of GDM if diet and lifestyle advice fail to
lower glucose adequately. Oral anti-diabetic agents
including metformin (a biguanide) and glibenclamide
(glyburide, a sulphonylurea) are increasingly considered
attractive alternatives to insulin with equivalent efficacy
to insulin, lower cost, ease of administration and patient
preference [6–9]. Metformin is now used as first-line
therapy in the UK, although both oral agents are
endorsed in national guidelines [1, 4]. In the USA,
glibenclamide is more widely used first-line with pre-
scriptions increasing from 7.4% in 2001 to 64.5% in
2011 [10]. Nevertheless, with reported “failure rates”
of metformin in three randomised studies between
32% and 46% [6, 11, 12], and of glibenclamide
between 16% and 25% [13–16], a significant number
of women require supplementary or alternative treat-
ment with insulin.
Combination treatment with sulphonylureas and
metformin is well established for treatment of type 2
diabetes in non-pregnancy [17–23] but has not (to
our knowledge) been tested in pregnancy [20–23].
Combination therapy may be a desirable approach for
women with GDM with glucose levels remaining
above the target range despite maximum tolerated
oral monotherapy. Such a regimen has the potential
to avoid the discomfort of subcutaneous injections
and the expense of insulin therapy. However, it is not
known whether using the combination therapy in
pregnancy is associated with increased risk of
hypoglycaemia or side effects, though neither are
more common with combination therapy in non-
pregnancy [20–23].
In women with GDM who failed to achieve adequate
glycaemic control on metformin monotherapy, we
hypothesised that combination therapy with glibencla-
mide, compared to insulin would result in similar
glycaemic control and clinical outcomes, and would be
preferable to women. In this feasibility study, we aimed to
determine the recruitment rate/participant throughput in
a randomised controlled trial of glibenclamide compared
with insulin (in addition to maximum tolerated metfor-
min), for the treatment of GDM and to explore glycaemic
control and compare clinical outcomes.
Methods
Study design and participants
We conducted an open-label feasibility study between
1st August 2014 and 31st October 2015 in antenatal
clinics at 5 NHS hospitals in Scotland, UK. Pregnant
women were eligible to participate if they had GDM (di-
agnosed using the definitions used at the recruiting sites
which are based on the International Association of the
Diabetes and Pregnancy Study Groups (IADPSG) criteria
of fasting plasma glucose ≥5.1 mmol/L or 2 h plasma
glucose during 75 g oral glucose tolerance test
≥8.5 mmol/L) and were failing to achieve adequate
glycaemic control despite maximum tolerated dose of
metformin, and were ≥16 weeks’ or ≤36 weeks’ gestation.
Inadequate glycaemic control was defined according to
criteria used in the Australian Carbohydrate Intolerance
Study in Pregnant women (ACHOIS) study [1] and
adopted in the relevant national guideline1 as more than
two home blood glucose readings during a fortnight of
any of fasting ≥5.5 mmol/L, 2 h post prandial ≥7 mmol/
L, or a post prandial value at any time ≥ 9 mmol/L. We
excluded women taking metformin dose <500 mg/ day;
women with suspected type 1 diabetes presenting in
pregnancy or marked hyperglycaemia (fasting ≥7 mmol/
L, 2 h ≥ 11.1 mmol/L); women with allergies to either
glibenclamide, insulin or any of their excipients; women
with contraindications to sulphonylurea therapy; and
women unable to give informed consent.
The study was approved by the Scotland A Research
Ethics Committee (reference number:13/SS/0223) and
the Medicines and Healthcare products Regulatory
Agency (EudraCT number:2013–004706-25) and was
registered with clinical trials.gov (registration num-
ber:NCT02080377). The trial was overseen by a Trial
Steering Committee and an independent Data Monito-
ring Committee.
Randomisation and masking
We randomly assigned women to receive glibenclamide
or insulin (standard care) in addition to their metformin
therapy using a secure web-based randomisation system
hosted by the NPEU Clinical Trials Unit, University of
Oxford. Randomisation used a minimisation algorithm
to ensure allocation concealment, target a 1:1 allocation
ratio and balance between the groups with respect to
study site, BMI status (BMI <40 or ≥40 kg/m2) recorded
at antenatal booking (typically between 11 and 13 weeks’
gestation) and multiplicity (singleton or multiple preg-
nancy). Neither participants nor caregivers/those collect-
ing outcome data were masked to treatment allocation;
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however, using minimisation made it impossible to
predict the next allocation with any certainty.
Procedures
Participants were given verbal and written information
about the study at the time of diagnosis of GDM. Prior to
recruitment, treatment with metformin was commenced
if women were failing to achieve adequate glycaemic con-
trol with lifestyle measures alone, according to standard
practice [1, 4]. Women were commenced on metformin
500 mg once daily and the dose up-titrated as tolerated to
a maximum of 2 g daily in two divided doses. If it became
clear that metformin therapy was insufficient to maintain
normoglycaemia, women were given further information
about the study. Those wishing to participate gave written
consent and were randomised. Demographics, medical
history, gestation of diagnosis of GDM and dose of
metformin therapy were recorded at the time of
randomisation.
Participants randomised to glibenclamide were pre-
scribed glibenclamide 2.5 mg once daily (time of day
decided by their clinician according to home blood
glucose monitoring) in addition to their current dose
of metformin. Glibenclamide therapy was up-titrated
to a maximum dose of 20 mg daily in two or three
divided doses during clinic visits by diabetes specialist
nurses and/or research midwives with diabetes/obstet-
ric medical support, according to a treatment algo-
rithm drawn up by consensus amongst study
clinicians at the start of the trial (RMR, MWJS, RL)
(Additional file 1: Fig. S1). All participating prescribers
received training in use of the algorithm. Women were
phoned three to five days after starting glibenclamide or
after any dose increase in glibenclamide, with up-titration
of treatment if sustained hyperglycaemia occurred.
Similarly, if hypoglycaemia occurred, the dose was down-
titrated. If women failed to achieve adequate glycaemic
control with dual oral therapy, glibenclamide was discon-
tinued and replaced with insulin therapy. Women rando-
mised to insulin (standard care) were treated according to
the clinician’s standard practice and doses adjusted to
achieve target glycaemic control. For those who achieved
normoglycaemia, allocation to glibenclamide or insulin
treatment, in combination with the maximum tolerated
dose of metformin, was maintained until delivery.
Participants were asked to check their blood glucose
4 times per day (fasting prior to breakfast, and 2 h
post-breakfast, lunch and evening meal). Data on the
participants’ blood glucose readings were directly
downloaded during each clinic visit from the home
blood glucose meter using the Diasend® platform
(Diasend Ltd., London, UK) into a Microsoft Excel
spreadsheet. We assumed that the first blood sample
of the day was a “fasting” sample, and that where
multiple readings of glucose were available within five
minutes of each other, the last of the series was the
correct reading. Clinical information was extracted
from the clinical record and details of daily drug
treatment were extracted from the participants’ treat-
ment diaries at each clinic visit. Clinical outcomes in-
cluding gestational weight gain, birthweight, gestation
at delivery, mode of delivery, and any complications
including neonatal hypoglycaemia were collected from
the clinical record post-delivery. Women were asked
to complete a questionnaire using a visual analogue
scale to assess satisfaction at 38–40 weeks gestation
and to answer the question ‘If you were given the
choice in the future, would you prefer to receive in-
sulin injections, or the glibenclamide tablets if you
had diabetes again?’
Outcomes
The primary outcome was the absolute number and
throughput/recruitment rate of eligible women with GDM
who were on maximum tolerated metformin and who
agreed to be randomised to glibenclamide or insulin.
Other key feasibility outcomes included: the proportion of
women who agreed to participate (uptake); the proportion
of women randomised who were retained in the study
(retention); the proportion of women who remained on al-
located treatment (adherence) and provided outcome data
(i.e. who were not lost to follow-up); the proportion of cli-
nicians who adhered to the protocol per se (compliance);
the safety of the two treatment regimens including the
number of episodes of hypoglycaemia needing treatment;
any other serious adverse events (SAEs, defined as an un-
toward medical occurrence that does not necessarily have
a causal relationship with the investigational medicinal
product but is life-threatening, requires hospitalisation,
consists of a birth defect or congenital abnormality, results
in death, persistent or significant incapacity or disability,
or any other serious medical event), and suspected unex-
pected serious adverse reactions (SUSARs, defined as any
adverse event that is serious and suspected to be causally
related to the investigational medicinal product).
Secondary outcomes were a) glycaemic control using
glucose values from downloaded home blood glucose
monitoring including number and percentage of excur-
sions in blood glucose below 3.5 mmol/L (defined in this
study as ‘hypoglycaemia’ [2]), and number and percentage
of excursions in blood glucose above or equal to
7.0 mmol/L at the 2 h post-prandial test, and above or
equal to 5.5 mmol/L at fasting test; b) participant satisfac-
tion; c) clinical outcomes including change in maternal
weight between booking and 36 weeks’ gestation, mode
and gestation of delivery, birthweight z-score (adjusted for
sex and gestation at birth), incidence of neonatal
hypoglycaemia (defined as any of the following: blood
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glucose <2.6 mmol/L in first 48 h of age, or given
intravenous glucose or any other drug to increase
blood glucose); d) other components of the primary
outcome used in the Metformin in Gestational
Diabetes (MIG) study [6] - Apgar less than 7, need
for phototherapy, respiratory distress syndrome (need
for at least 4 h of respiratory support with supple-
mental oxygen, continuous positive airway pressure,
or intermittent positive-pressure ventilation during
the first 24 h after delivery), birth trauma (injury to
the baby at delivery, defined as mild if bruises or
abrasions were present at birth but resolved before
6 weeks post-partum; or moderate or serious for
other injuries including fractures, Erb’s palsy and
brachial plexus injuries).
Statistical analysis
We aimed to randomise at least 22 women to each arm
(total n = 44). As this was a feasibility study a formal
power calculation was not considered appropriate [24].
Analysis was conducted in the intention-to-treat popu-
lation. Maternal and infant demographic and clinical
characteristics were described at baseline.
For analysis of the primary outcome, the mean and
standard deviation are presented with 95% confidence
intervals for the monthly recruitment rate, overall and
by centre, and the overall recruitment rate/centre/
month, assuming a Poisson distribution. For the other
feasibility metrics (uptake rate, retention, adherence),
counts and percentages were calculated (by trial arm,
where appropriate) with overall 95% confidence intervals
(CI). Safety outcomes are presented as counts and
percentages of occurrences, by trial arm.
Unadjusted comparative analyses were performed for
clinical outcomes, except where the number of events in
either arm was less than 2, in which case overall counts
with 95% CIs were given. For continuous outcomes,
results are given as differences in means, or differences
in medians (if the data were skewed) with 95% CIs. For
binary or categorical outcomes, risk ratios with corre-
sponding CIs were calculated. Participant satisfaction
was presented as counts and percentages by trial arm,
and overall 95% CIs. Blood glucose outcomes (waking
and post-prandial) were compared by trial arm. To ad-
just for variation in the duration of therapy in the
groups, prior to unblinding it was agreed to determine
number of excursions per woman, per week of treat-
ment, and to present the number and percentage of
women with at least one excursion. Some post-hoc ex-
ploratory comparisons were made on the blood glucose
readings including on the number of blood glucose rea-
dings, and the number of readings per woman per day;
the overall variation in the readings. Excursions in blood
glucose were compared using the number of women
with at least one excursion by trial arm, with risk ratios
and 95% CIs. The number of excursions/woman/week
was also summarised using medians (IQR), and compared
by trial arm with the median difference and 95% CI.
Stata/SE for Windows (version 13.1) was used for all
analyses.
Results
We screened 197 pregnant women with GDM who were
taking metformin, 25 of whom satisfied the clinical eligi-
bility criteria (CONSORT flow chart, Fig. 1). Of these,
23 women (92%, 95%CI 74–99%) agreed to participate in
the trial, equivalent to a mean recruitment rate (SD) of
0.39 (0.62) women/centre/month. The most common
reason for non-participation was that satisfactory
glycaemic control was achieved with metformin mono-
therapy prior to 36 weeks’ gestation, with 107/174 (61%)
of women expressing initial interest in the study being
effectively treated with metformin monotherapy. The 23
participants were randomly assigned to glibenclamide
(n = 13) or insulin (n = 10) in addition to metformin
therapy, and all were included in the analyses of primary
and secondary outcomes, i.e. no post-randomisation ex-
clusions and 100% retention (Fig. 1). Adherence to the
glibenclamide intervention was achieved in 9/13 (69.2%,
95%CI 38.6–90.9%) women, with 4 women switched to
insulin therapy due to hyperglycaemia (n = 2) or
hypoglycaemia (n = 2).
Baseline demographics and dose of metformin at re-
cruitment to the study were broadly similar between
groups, although women randomised to glibenclamide
tended to be diagnosed with GDM earlier in pregnancy,
and to be of higher body mass index (Table 1).
Our pre-specified primary safety outcome was
hypoglycaemia requiring assistance – none of the women
in either group experienced this or any other SUSAR
(Table 2). There were four women with a serious adverse
event - three with a post-partum haemorrhage and one
with sepsis, but these were equally distributed between
the groups (Table 2). Women treated with glibenclamide
had significantly more episodes of asymptomatic
hypoglycaemia per week (median difference (IQR) of
number of excursions <3.5 mmol/L per woman per week
0.58 (0.03 to 1.87)) (Additional file 2: Table S1) and tended
to have more fasting excursions ≥5.5 mmol/L (median
difference (IQR) of number of excursions per woman per
week 0.50 (−0.55 to 2.33)) and higher post-prandial glu-
cose excursions (Additional file 2: Table S1 and Fig. 2).
Among participants randomised to glibenclamide, the
majority expressed a preference for glibenclamide therapy
(Additional file 2: Table S2). However, only 1 woman
(12.5% of those expressing a preference) who was rando-
mised to insulin expressed a preference for glibenclamide,
and 3 women did not complete the questionnaire (1 in
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glibenclamide group, 2 in insulin group). There were no
significant differences between groups in any of the other
secondary outcomes including gestational weight gain,
birthweight, gestation at delivery, mode of delivery and
other complications including neonatal hypoglycaemia, al-
though both episodes of neonatal hypoglycaemia were in
the group whose mothers were treated with glibenclamide
(in addition to metformin) (Additional file 2: Table S2 and
Additional file 2: Table S3).
Discussion
Main findings
Based on our recruitment rates of 0.39 women/centre/
month, we estimate that a large randomised trial of glib-
enclamide compared with insulin (assuming a sample
size of between 500 and 800) would require 30–60
centres recruiting for 3 years. Such a study is likely to be
feasible, but expensive. However, our prior hypothesis
that glibenclamide and insulin would be equivalent in
terms of glycaemic and clinical outcomes appears incor-
rect, given that we showed significantly greater frequen-
cies of excursions in blood glucose below 3.5 mmol/L in
the glibenclamide group. Preference for oral therapy was
not universal, with 45% of all participants either express-
ing no preference or preferring insulin.
Interpretation
The combination of glibenclamide and metformin appears
worse than the combination of insulin and metformin.
Contrary to our expectations about the unattractiveness of
subcutaneous injections, women did not universally ex-
press a preference for glibenclamide over insulin. Hence
we believe that further trials of glibenclamide and metfor-
min in pregnancy in unselected women with GDM are
unwarranted. In this small sample, preliminary data
suggest that insulin (in combination with metformin)
gives superior glycaemic control, with a lower incidence of
glucose excursions <3.5 mmol/L (compared with gliben-
clamide in combination with metformin). A recent sys-
tematic review of drug treatments for GDM highlighted
an increased risk of neonatal hypoglycaemia with gliben-
clamide compared with insulin monotherapy [25]. The
pharmacokinetics of metformin are unchanged in preg-
nancy, whereas oral clearance rates of glibenclamide
Fig. 1 CONSORT flow chart
Reynolds et al. BMC Pregnancy and Childbirth  (2017) 17:316 Page 5 of 9
increase [26, 27]. Whether there are further changes in
pharmacokinetics of the two drugs used in combination in
pregnancy is unknown. Metformin crosses the placenta,
but there is debate about whether this is true for glibencla-
mide [26, 27]. Other factors which may have contributed
to the poorer glycaemic control in the glibenclamide arm
of our trial include limited flexibility to titrate doses (smal-
lest tablet dose was 2.5 mg) and inexperience of clinicians
with titrating doses due to lack of routine use of glibencla-
mide, which has largely been replaced by sulphonylureas
with a shorter duration of action (gliclazide, glipizide) in
diabetes practice in the UK. Our other secondary
outcomes showed no differences between treatment with
glibenclamide or insulin, but must be interpreted with
caution due to the small sample size.
We were surprised to find little evidence of preference
for oral therapy. A previous study found no increase in
anxiety and depression symptoms in women with GDM
when treatment was intensified from diet alone to insu-
lin therapy [28]. Another study indicated the dominant
concern in women with GDM was ‘the baby’s health’,
whereas treatment satisfaction was generally high [29].
A woman’s concerns about choice of adjuvant therapy
for GDM when metformin has failed are also likely to be
different from individuals with type 2 diabetes [30] due
to the much shorter duration of need for therapy.
Strengths and limitations
The strengths of our study include the robust multicen-
tre randomised controlled design, and the statistically
Table 1 Maternal characteristics at baseline (n = 23)
Intervention (Glibenclamide)(n = 13) Standard (Insulin) (n = 10) Total (n = 23)
Maternal age (years) Mean (SD) 33.0 (5.1) 34.5 (4.9) 33.7 (5.0)
BMI (kg/m2) at randomisation
< 40 n (%) 8 (61.5) 8 (80.0) 16 (69.6)
≥ 40 n (%) 5 (38.5) 2 (20.0) 7 (30.4)
Median [IQR] 39.2 [33.2 to 40.6] 33.3 [29.5 to 38.2] 35.7 [32.0 to 40.5]
Gestational age at randomisation
(weeks)
Mean (SD) 29.6 (6.3) 31.5 (2.2) 30.4 (4.9)
Gestation at diagnosis of gestational
diabetes (weeks)
Median [IQR] 24.9 [17.6 to 28.9] 27.1[24.0 to 28.9] 26.7[17.6 to 28.9]
Daily dose of metformin at
randomisation (mg)
Median [IQR] 1500 [1500 to 2000] 1500 [1500 to 2000] 1500 [1500 to 2000]
Ethnicity
White n (%) 10 (76.9) 7 (70.0) 17 (73.9)
Indian n (%) 0 (0.0) 2 (20.0) 2 (8.7)
Pakistani n (%) 1 (7.7) 1 (10.0) 2 (8.7)
Bangladeshi n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Other Asian background n (%) 1 (7.7) 0 (0.0) 1 (4.4)
Black n (%) 1 (7.7) 0 (0.0) 1 (4.4)
Deprivation levela
1 (Most deprived) n (%) 6 (46.2) 4 (40.0) 10 (43.5)
2 n (%) 3 (23.1) 2 (20.0) 5 (21.7)
3 n (%) 1 (7.7) 0 (0.0) 1 (4.3)
4 n (%) 2 (15.4) 1 (10.0) 3 (13.0)
5 (Least deprived) n (%) 1 (7.7) 3 (30.0) 4 (17.4)
Number of previous pregnanciesb
0 n (%) 1 (7.7) 2 (22.2) 3 (13.6)
1 or more n (%) 12 (92.3) 7 (77.8) 19 (86.4)
Blood pressure (mmHg)
Systolic Mean (SD) 118.4 (11.4) 122.2 (10.8) 120.0 (11.0)
Diastolic Mean (SD) 72.2 (7.0) 72.6 (8.7) 72.3 (7.6)
a From the Scottish Index of Multiple Deprivation http://www.isdscotland.org/Products-and-Services/GPD-Support/Deprivation/SIMD/index.asp?Co=Y
b All lengths, including miscarriages; data missing from 1 participant in the insulin-treatment group
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significant difference in hypoglycaemic episodes in associ-
ation with glibenclamide. We also demonstrate that using
routinely collected clinical data including downloads of
home-blood glucose measurements gives a wealth of in-
formation about maternal glycaemic control in ‘real life’.
We do not believe that the open-label design impacted on
outcome, as an algorithm was used by all clinicians for ti-
tration of medication doses and to guide decisions for ‘res-
cue’ therapy. The limitations of the study include the
small sample size, which could have contributed to a
chance imbalance on prognostic factors including weight
and time of diagnosis. The lower than planned recruit-
ment rate to our study occurred principally because the
majority of women achieved adequate glycaemic control
with metformin monotherapy, though rates of metformin
‘failure’ in around a third of women were consistent with
other published studies [6, 11, 12]. A further limitation is
that the lack of ethnic diversity in our sample mean our
findings may not be generalisable, though we are not
aware of any studies showing ethnic differences in
responses to either metformin or glibenclamide mono-
therapy in pregnancy.
Conclusions
In conclusion, this small feasibility study shows that a
large randomised controlled trial comparing additional
glibenclamide or insulin in women with GDM who are
failing to achieve adequate glycaemic control with met-
formin alone is feasible, but is unlikely to be clinically
worthwhile given both the poorer glycaemic control with
glibenclamide and metformin in this pilot study and the
lack of universal preference for glibenclamide over insu-
lin. The lack of adverse effects in our study suggests that
the combination of metformin and glibenclamide may
be considered as treatment option for selected individual
women with GDM who are failing metformin monother-
apy, if there is careful monitoring of glycaemic control.
Such an option may be useful for women with a needle
phobia, women with an inability to use insulin therapy
or where insulin is unavailable.
Table 2 Feasibility outcomes
Intervention
(Glibenclamide)
(n = 13)
Standard
(Insulin)
(n = 10)
Total
(n = 23)
(95% CI)
Primary outcome: Number of women who agreed to be randomised
Overall monthly recruitment rate (15.8 months) a Mean {SD} 1.45 {1.21}
(0.92 to 2.18)
Recruitment rate per centre per month (58.9 months) b Mean {SD} 0.39 {0.62}
(0.25 to 0.59)
Uptake rate
Total number of women eligible n 25
Proportion of those eligiblec agreeing to be randomised n (%) 23 (92.0)
(74.0% to 99.0%)
Retentiond
Number of women who remained in the study n (%) 13 (100.0) 10 (100.0) 23 (100.0)
(85.2% to 100.0%)
Adherence - Adhered to the treatment regimene n (%) 9f (69.2)
(95% CI) (38.6% to 90.9%)
Safetyg
Number of women with hypoglycaemic episodes needing treatment n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Number of women with SUSARs n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Number of women with SAEs n (%) 2 (15.4) 2 (20.0) 4 (17.4)
Number of women with other adverse events n(%) 0 (0.0) 0 (0.0) 0 (0.0)
a Numerator is the number of women randomised, denominator is the total length the trial was recruiting (15.8 months)
b Numerator is the number of women randomised, denominator is the sum of the length of time each centre was open (58.9 months)
c Eligible women defined as those who were recruited or declined to participate but were known to be clinically eligible
d Proportion of women who delivered and remained in the study to provide outcomes
e Glibenclamide allocation only – indicates women who did not switch from Glibenclamide to insulin to maintain normoglycaemia
f 4 switched for the following reasons:
2 because blood glucose measurements were high
1 not achieving adequate glycaemic control on insulin. Fasting sugars high but occasional low sugars at lunch
1 sugars too low with Glibenclamide, but too high without
g As per ITT, provided that they received at least one dose of the treatment allocated
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